AMSBIO has introduced a new range of proprietary reagents designed for researchers investigating targeted cancer therapy.
Targeted cancer therapy represents a promising new cancer treatment, one which delivers drugs in specific carriers and interferes with the specific target molecules that play a critical role in tumour growth and progression. Exosomes expressing specific surface markers (among them CD81, CD63, and CD9) have been found to play roles in cancer progression and tumorigenesis as a transporter of miRNA. As a delivery system, they can therefore potentially be used as a specific carrier of immunotherapy/chemotherapy and cancer vaccines, as can be seen in a growing number of biotech companies, such as Evox Therapeutics developing exosome-based therapies.
The new column-based exosome isolation kit from AMSBIO works to isolate intact exosomes from both serum and cell-conditioned media. Exosome detection ELISA kits quantify exosome levels in the fractions as well as in samples such as culture media and sera. In addition, AMSBIO also provides monoclonal antibodies against common exosome markers and immune checkpoint ligands for immunostaining, ELISA, or flow cytometry.
AMSBIO offers a wide selection of products dedicated to Exosome Research. This includes high quality reagents and kits that are quick, affordable and easy to use.
AMSBIO will be exhibiting its complete range of products for exosome research at the forthcoming meeting of the Belgian Society for Extracellular Vesicles in October: see https://www.bscdb.be/autumn-meeting-2019
For further information on these new introductions to AMSBIO’s extensive range of products for exosome research please visit www.amsbio.com/exosomes.aspx or contact the company on +44-1235-828200 / +1-617-945-5033 / firstname.lastname@example.org.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics.
For drug discovery research, AMSBIO offers assays, recombinant proteins and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications these include high quality solutions for viral delivery (lentivirus, adenovirus and adeno-associated virus) in addition to GMP cryopreservation technology.
AMS Biotechnology (AMSBIO)
184 Milton Park
Oxon OX14 4SE
Dr Bill Bradbury email@example.com